Journal
PHARMACOGENOMICS
Volume 10, Issue 1, Pages 59-68Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/14622416.10.1.59
Keywords
cancer genetics; EGFR; lung cancer; predictive markers
Categories
Funding
- NIH [R01CA92824, R01CA074386, K12 CA087723]
- NATIONAL CANCER INSTITUTE [R01CA092824, K12CA087723, R01CA074386] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular tyrosine kinase inhibitors, such as erlotinib or gefitinib, or monoclonal antibodies such as cetuximab. A growing body of evidence is identifying potential molecular predictors of response and toxicity. This includes tumor-related molecular markers, such as EGFR mutation and copy number, as well as germline markers such as polymorphisms in EGFR or EGFR pathway-related genes. This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available